Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study

AIMS: Patients with type 2 diabetes and non‐alcoholic fatty liver disease (NAFLD) exhibit considerable residual risk for cardiovascular disease (CVD). There is, therefore, increasing interest in targeting postprandial lipid metabolism and remnant cholesterol. Treatment with the glucagon‐like peptide...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Diabetes Obes Metab
Prif Awduron: Matikainen, Niina, Söderlund, Sanni, Björnson, Elias, Pietiläinen, Kirsi, Hakkarainen, Antti, Lundbom, Nina, Taskinen, Marja‐Riitta, Borén, Jan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Ltd 2018
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585708/
https://ncbi.nlm.nih.gov/pubmed/30073766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13487
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg